Ovarian cancer patients who have an inherited BRCA mutation, and who responded to platinum-based chemotherapy, benefit from using Lynparza (olaparib) tablets as a maintenance treatment, a clinical trial suggests. The Phase 3 SOLO-2 trial (NCT01874353) of the AstraZeneca therapy in tablet form met its primary goal of increasing patients' progression-free survival -- the length of time their disease fails to worsen. Patients on the tablets lived 13.6 months longer than those on a placebo, the trial investigators said. The U.S. Food and Drug Administration (FDA) has approved Lynparza capsules for use against cancer, but not the tablet form yet. Another measure of progression-free survival in the SOLO-2 trial, the Blinded Independent Central Review (BICR) scale, suggested an even larger 24.7-month improvement in the tablet takers' progression-free survival. The results were presented at the Society of Gynecologic Oncology Annual Meeting on Women’s Cancer March 13-15 in National Harbor, Maryland. “The SOLO-2 data demonstrated a statistically significant and clinically meaningful improvement in outcomes for those who took olaparib," Richard Penson, MD, associate professor of Medicine at Harvard Medical School, said in a news release. "The results, which showed a delay in disease progression in the maintenance setting, highlight the impact of PARP inhibition at the forefront of the important advances we are making in targeting ovarian cancer,"